*ST生物拟收购慧泽医药51%股权

Core Viewpoint - *ST Bio is planning to acquire a 51% stake in Hunan Huize Biomedical Technology Co., Ltd. for cash, which will make Huize a subsidiary and included in the consolidated financial statements [1] Group 1: Acquisition Details - The acquisition aims to enhance the company's industrial chain layout by leveraging Huize's technological accumulation and customer resources in drug research and clinical evaluation [1] - Following the announcement, *ST Bio has experienced two consecutive trading days of limit-up gains [1]